Literature DB >> 16083310

Inhibition of vascular endothelial growth factor-induced retinal neovascularization by retinoic acid in experimental retinopathy of prematurity.

H Ozkan1, N Duman, A Kumral, B Kasap, E A Ozer, B Lebe, A Yaman, T Berk, O Yilmaz, E Ozer.   

Abstract

Vascular endothelial growth factor (VEGF) has an important role in the pathogenesis of retinopathy of prematurity (ROP) and inhibition of VEGF expression in the neovascular phase might prevent destructive neovascularization in ROP. It is suggested that retinoids exert a highly potent antiangiogenic activity by inhibiting VEGF expression. The aim of this study was to demonstrate the preventive effect of retinoic acid (RA) on the VEGF-induced retinal neovascularization in a rat model of ROP. Wistar albino rats were placed into incubators at birth and exposed to an atmosphere alternating between 50 % and 10 % O(2) every 24 hours. After 14 days, the animals were removed to room air and received either an intraperitoneal injection of RA (5 mg/kg/day) (n=9) or saline (n=4) daily for six days, and sacrificed at 21 days. Other rats (n=4) were raised in room air and served as age-matched controls. The globe of each eye was cut through the cornea and embedded in paraffin. Serial sections were stained with hematoxylin-eosin for quantification of neovascular nuclei. The avidin-biotin peroxidase method was performed for evaluation of VEGF expression. The average number of neovascular nuclei was significantly lower in the control group compared to that in the ROP groups. In addition, it significantly decreased in the RA-treated ROP group compared to that of the saline-administrated ROP group. VEGF immunostaining was overall negative in room air-exposed rats. The VEGF immunostaining score significantly decreased in the RA-treated ROP group compared to that in the saline-administered ROP group. RA treatment might be beneficial in preventing neovascularization resulting from oxygen-induced retinopathy by downregulation of VEGF expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16083310     DOI: 10.33549/physiolres.930754

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  7 in total

Review 1.  [Vitamin A level and diseases of premature infants].

Authors:  En-Fu Tao; Tian-Ming Yuan
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2016-02

2.  Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity.

Authors:  Raul Velez-Montoya; Carmen Clapp; Jose Carlos Rivera; Gerardo Garcia-Aguirre; Virgilio Morales-Cantón; Jans Fromow-Guerra; Jose Luis Guerrero-Naranjo; Hugo Quiroz-Mercado
Journal:  Clin Ophthalmol       Date:  2010-09-07

Review 3.  A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases.

Authors:  Ashley Stark; Christiane Dammann; Heber C Nielsen; MaryAnn V Volpe
Journal:  Front Pediatr       Date:  2018-06-13       Impact factor: 3.418

4.  EARLY VITAMIN A SUPPLEMENTATION IMPROVES THE OUTCOME OF RETINOPATHY OF PREMATURITY IN EXTREMELY PRETERM INFANTS.

Authors:  Huiqing Sun; Rui Cheng; Zhansheng Wang
Journal:  Retina       Date:  2020-06       Impact factor: 3.975

5.  Retinoic acid regulates erythropoietin production cooperatively with hypoxia-inducible factors in human iPSC-derived erythropoietin-producing cells.

Authors:  Naoko Katagiri; Hirofumi Hitomi; Shin-Ichi Mae; Maki Kotaka; Li Lei; Takuya Yamamoto; Akira Nishiyama; Kenji Osafune
Journal:  Sci Rep       Date:  2021-02-16       Impact factor: 4.996

Review 6.  Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again.

Authors:  Mitsuru Arima; Yuya Fujii; Koh-Hei Sonoda
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

Review 7.  New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics.

Authors:  Juhee Ryu
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.